Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose - ADERE PROJECT (ADERE (Ped))
Primary Purpose
Asthma
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Telephone follow-up
No telephone follow-up
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring Treatment compliance, Pediatric, Asthma
Eligibility Criteria
Inclusion criteria:
- Signature of a informed consent form
- Age between 6 and 14 years old
- Diagnosis of persistent moderate or severe asthma, according to III Brazilian Consensus on Asthma Management.
- Home telephone available
Exclusion criteria:
- Co-morbidities that may interfere with the study evaluation or that require continuous drugs, e.g., cardiopathy, gastro-esophageal reflux or diabetes.
- Continuous systemic corticosteroid use for more than seven days
- The patient has been treated or is being treated with allergen-specific immunetherapy
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
telephone follow-up
No telephone follow-up
Arm Description
Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
Outcomes
Primary Outcome Measures
The main outcome, compliance, is being measured by the number of doses used of the drug salmeterol combined with fluticasone (Seretide Diskus) divided by the number of doses foreseen for the time considered.
Secondary Outcome Measures
Disease control, evaluated by information in the questionnaires.
Regular medical attention sought, evaluated by information in the questionnaires
Additional resources in the event of attacks
Improvement in the quality of life.
Increase in the weekly number of nocturnal awakening or the number of awakenings per night
Increase in the use of rescue drug
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01476059
Brief Title
Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose - ADERE PROJECT
Acronym
ADERE (Ped)
Official Title
Prospective, Parallel-group, Randomized Study to Evaluate the Compliance to the Treatment of Children Aged Between 6 and 14 Years Old With Persistent Moderate or Severe Asthma, Receiving the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose Twice a Day. ADERE PROJECT
Study Type
Interventional
2. Study Status
Record Verification Date
June 2017
Overall Recruitment Status
Completed
Study Start Date
May 2004 (undefined)
Primary Completion Date
December 2004 (Actual)
Study Completion Date
December 2004 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GlaxoSmithKline
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Prospective, parallel-group, randomized study to evaluate the compliance to the treatment of children aged between 6 and 14 years old with persistent moderate or severe asthma, receiving the association Fluticasone 250 mcg/dose and Salmeterol 50 mcg/dose twice a day.
ADERE PROJECT (Pediatric)
Detailed Description
Objectives
General:
To evaluate the compliance degree to the treatment of asthmatic children, according to the attention received.
Specific:
To study asthmatic compliance to the treatment proposed, aiming at an association with other factors, such as: parents' instruction, hospitalizations, personal and family history of atopy, co-morbidities, severity of the disease and use of other drugs.
To study asthmatic compliance to the treatment proposed, associating it with the impact in quality of life, though the application of a specific questionnaire.
Outcomes
The main outcome, compliance, is being measured by the number of doses used of the drug salmeterol combined with fluticasone (Seretide Diskus) divided by the number of doses foreseen for the time considered.
The following will be considered as secondary outcomes:
Disease control, evaluated by information in the questionnaires.
Regular medical attention sought, evaluated by information in the questionnaires.
Additional resources in the event of attacks, increase in the weekly number of nocturnal awakening or the number of awakenings per night, increase in the use of rescue drug.
Improvement in the quality of life.
Casuistic and Method
Study groups
Asthmatic children aged 6 to 14 years old from both sexes, with persistent mild, moderate or sever asthma classified according to the criteria from the III - Brazilian Consensus on Asthma Management.
Group I - Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
Group II - Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
Study Design
This is a prospective, controlled, randomized, parallel-group study, with the inclusion of 472 children presenting persistent moderate or severe asthma. Our researchers developed the study, and it will be performed only in Brazil, solely by our Clinical Research Center. The drug to be used is in accordance with the main International Consensus on Asthma Treatment and with the III - Brazilian Consensus on Asthma Management, being marketed for some years in Brazil.
During patient recruitment and screening, their parents or guardians will fill out the free informed consent form. At this time, they will also be given the drug (Seretide Diskus® 50/250) with doses enough for a 90-day treatment, twice a day, in addition to instructions on the use of the device to apply the drug and guidance from his/her physician on how to act in the event of an attack.
After study inclusion, the study will receive a number which will randomly include him/her in group 1 or 2 of this study.
Patients included in group 1 will receive two types of telephone calls:
A. Investigation telephone call - TI: that will be made by a trained health professional from the Centro de Pesquisa Clínica e Medicina Avançada, aiming at: presentation, data collection on asthma, including demographics and relevant clinical history (details on asthma, previous exacerbations, drugs used, etc), submission of a standardized checking questionnaire (questionnaire 1 - attachment 1) and quality of life questionnaire (questionnaire 2 - attachment 2). By 90 days, the patient's guardian will receive the last investigation telephone call (TI -2) in order to apply the quality of life questionnaire and standardized evaluation questionnaire (questionnaire 1 - attachment 1)
B. Compliance telephone call - TA: A specifically trained professional will make follow-up telephone calls at every fifteen days, according to a pre-established guide (Attachment 4), requesting the patient to answer the questions pursuant to the follow-up questionnaire (attachment 3) and clarifying probable doubts on the drug application, however, without interfering with the treatment prescribed by the physician.
Patients included in group 2 will receive only the Investigation Telephone call (TI) All telephone contacts will be made for the same person: mother, father or guardian.
By the end of week 12, the persons responsible for the patients will return, by mail, the drug to Centro de Pesquisa Clínica e Medicina Avançada.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Treatment compliance, Pediatric, Asthma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
472 (Actual)
8. Arms, Groups, and Interventions
Arm Title
telephone follow-up
Arm Type
Other
Arm Description
Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
Arm Title
No telephone follow-up
Arm Type
Other
Arm Description
Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
Intervention Type
Other
Intervention Name(s)
Telephone follow-up
Intervention Description
Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
Intervention Type
Other
Intervention Name(s)
No telephone follow-up
Intervention Description
Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
Primary Outcome Measure Information:
Title
The main outcome, compliance, is being measured by the number of doses used of the drug salmeterol combined with fluticasone (Seretide Diskus) divided by the number of doses foreseen for the time considered.
Time Frame
After 90 days of treatment
Secondary Outcome Measure Information:
Title
Disease control, evaluated by information in the questionnaires.
Time Frame
After 90 days of treatment
Title
Regular medical attention sought, evaluated by information in the questionnaires
Time Frame
After 90 days of treatment
Title
Additional resources in the event of attacks
Time Frame
After 90 days of treatment
Title
Improvement in the quality of life.
Time Frame
After 90 days of treatment
Title
Increase in the weekly number of nocturnal awakening or the number of awakenings per night
Time Frame
After 90 days of treatment
Title
Increase in the use of rescue drug
Time Frame
After 90 days of treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
14 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Signature of a informed consent form
Age between 6 and 14 years old
Diagnosis of persistent moderate or severe asthma, according to III Brazilian Consensus on Asthma Management.
Home telephone available
Exclusion criteria:
Co-morbidities that may interfere with the study evaluation or that require continuous drugs, e.g., cardiopathy, gastro-esophageal reflux or diabetes.
Continuous systemic corticosteroid use for more than seven days
The patient has been treated or is being treated with allergen-specific immunetherapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GSK Clinical Trials
Organizational Affiliation
GlaxoSmithKline
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose - ADERE PROJECT
We'll reach out to this number within 24 hrs